Using Dendritic Cells to Improve Bladder Cancer Treatment
Author Information
Author(s): H Atkins, B R Davies, J A Kirby, J D Kelly
Primary Institution: Northern Institute for Cancer Research, University of Newcastle
Hypothesis
The immune response elicited by BCG is suboptimal and potentially antagonistic, which might limit the survival of some patients with bladder cancer.
Conclusion
Stimulation of dendritic cells with CpG-oligonucleotides can polarize the immune response towards a more effective Th1 phenotype for bladder cancer immunotherapy.
Supporting Evidence
- BCG therapy induces a mixed Th1 and Th2 immune response.
- Stimulation with CpG-oligonucleotides leads to increased IL-12 production without IL-10.
- Poor polarization of the immune response may contribute to treatment failure in bladder cancer.
Takeaway
This study shows that a special treatment can help the body's immune system fight bladder cancer better by using certain molecules that tell immune cells what to do.
Methodology
The study involved culturing dendritic cells from mouse bone marrow and stimulating them with BCG and CpG-oligonucleotides to assess cytokine production and immune response.
Limitations
The study was conducted in mice, which may not fully replicate human responses.
Participant Demographics
Female C3H/HeSn and C3H/HeJ mice, aged 8-10 weeks.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website